Barely Significant
← all excerpts

O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.

ACS Chem Neurosci · 2022 · PMC9026285 · PMID 35357812

1
hedged sentence
closest p
boldest claim

The sentences

highly significantno p-value reported
A highly significant correlation ( R 2 = 0.99) between the brain and PBMC O-GlcNAcylation was also seen, implying that peripheral and CNS OGA enzyme activities are equally inhibited by ASN90 ( Figure 2 D).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.